TuberculosisNCT00266383
The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population
An observational study of Tuberculosis, run by National Health Research Institutes, Taiwan at 1 site in Taiwan.
Trial summary
The human homologue of mice natural-resistance-associated macrophage protein 1 (Nramp 1) gene, NRAMP 1, has been reported to play a role in the susceptibility to tuberculosis in humans. The aboriginal population in Taiwan has a 5-fold higher prevalence of tuberculosis than the Han Chinese. Read more about this study
- Who is it for?
- Ages 0 years and older
- Conditions the study is for
- Tuberculosis
- How many people
- 250 participants
- Where
- 1 siteTaiwan
- Study dates
- Jan 2005to Dec 2005
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- The NRAMP 1 polymorphism of tuberculous patients in Taiwan.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
The human homologue of mice natural-resistance-associated macrophage protein 1 (Nramp 1) gene, NRAMP 1, has been reported to play a role in the susceptibility to tuberculosis in humans. The aboriginal population in Taiwan has a 5-fold higher prevalence of tuberculosis than the Han Chinese. Whether genetic factors such as NRAMP 1 polymorphisms play a role in the prevalence of tuberculosis in Taiwanese aboriginals should be clarified.
- Conditions
- Tuberculosis
- Medical subject headings
- Tuberculosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2005 (estimated)
- Study startJan 2005
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 250 participants
Sponsor and investigators
- Lead sponsor
- National Health Research Institutes, Taiwan
- Sponsor type
- University, hospital or other
- Investigators
- Ih-Jen Su, M.D., Ph.D., Principal investigator, Division of Clinical Research, National Health Research Institutes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00266383
- Sponsor's protocol ID
- DOH94-DC-1009
- Status last verified
- Dec 2005
- First submitted
- 15 Dec 2005
- Last updated
- 19 Dec 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population
- ClinicalTrials.gov ID
- NCT00266383
- Acronym / sponsor ID
- DOH94-DC-1009
- Conditions
- Tuberculosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 250 participants
- Lead sponsor
- National Health Research Institutes, TaiwanUniversity, hospital or other
- Study start
- Jan 2005
- Study completion
- Dec 2005
- First posted
- 16 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The human homologue of mice natural-resistance-associated macrophage protein 1 (Nramp 1) gene, NRAMP 1, has been reported to play a role in the susceptibility to tuberculosis in humans. The aboriginal population in Taiwan has a 5-fold higher prevalence of tuberculosis than the Han Chinese. Whether genetic factors such as NRAMP 1 polymorphisms play a role in the prevalence of tuberculosis in Taiwanese aboriginals should be clarified.
Study design
- Observational model
- Case-control
- Time perspective
- Other
Who may qualify
- Ages
- 0 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- The NRAMP 1 polymorphism of tuberculous patients in Taiwan.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2005.
Related trials for Tuberculosis
RecruitingPhase 4
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Mycobacterium Avium Complex Pulmonary Disease
RecruitingObservational study
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Tuberculosis
Not yet recruitingPhase 2
Re-evaluating the Duration in Children of TB Treatment
Tuberculosis
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Active, not recruitingPhase 3
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Tuberculosis, MDR
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ih-Jen Su, M.D., Ph.D. principal investigator
Division of Clinical Research, National Health Research Institutes
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tuberculosis, run by National Health Research Institutes, Taiwan at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2005.